Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.50 USD

29.50
21,432,521

+0.19 (0.65%)

Updated Sep 24, 2024 04:01 PM ET

After-Market: $29.52 +0.02 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Chevron & ServiceNow

Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Chevron Corporation (CVX) and ServiceNow, Inc. (NOW), as well as two micro-cap stocks Sypris Solutions, Inc. (SYPR) and Mobile Infrastructure Corporation (BEEP).

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.

EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

Here's Why Pfizer (PFE) Fell More Than Broader Market

In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.

Roche Antiviral Drug Reduces Transmission in Late-stage Study

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.

Kinjel Shah headshot

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Lilly Gets FDA Approval for Eczema Drug Ebglyss

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

Andrew Rocco headshot

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

Nalak Das headshot

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.

Rajani Lohia headshot

5 Bargain Price-to-Sales Stocks With High Growth Prospects

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, HG, BBSI and PFE hold promise.

Ahan Chakraborty headshot

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.

Pfizer (PFE) Upgraded to Buy: What Does It Mean for the Stock?

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PFE or NVO: Which Is the Better Value Stock Right Now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Why Pfizer (PFE) Outpaced the Stock Market Today

In the most recent trading session, Pfizer (PFE) closed at $29.74, indicating a +1.11% shift from the previous trading day.

Relay Stock Soars on Upbeat Data From Breast Cancer Study

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.